Neoadjuvant chemotherapy (NAC) is increasingly used in breast cancer (BC), especially for downstaging the primary tumor in the breast and the metastatic axillary lymph nodes. Accurate evaluations of the response to neoadjuvant chemotherapy provide important information on the impact of systemic therapies on breast cancer biology, prognosis, and guidance for further therapy. This study was to assess short-term and oncological outcomes of NAC for early stage of breast cancer in Vietnamese population. Methods: A retrospective study was conducted from January 2020 to December 2022 with 200 patients who completed NAC for early stage of BC. The patients then underwent a radical surgery or not depending on clinical response. Short-term outcomes included clinical response based on the Response Evaluation Criteria in Solid Tumor version 1.1, adverse events assessed by the National Cancer Institute-Common Toxicity Criteria for Adverse Event, and rate of pCR (pathological complete responses) which is associated with recurrence and death. Results: Mean age was 52 years and 99.5% of patients were female. All patients were classified clinically as stage II (47%) and stage III (53%). Clinical responses were achieved in all patients, but only 6/200 patients (3.0%) got complete clinical responses. Most patients (99.5%) underwent surgery after NAC but pCR was only 17.1%. Two-year progression free survival (PFS) was 86.6%. Patients with pCR had significantly higher survival rate than those without complete response. Conclusions: NAC for early stage of breast cancer is safe and increasing radical surgery. Even when pCR is not achieved, NAC nevertheless allows us to triage patients who did not achieve pCR so that they can be treated using additional therapy. Therefore, accurate evaluation of the response to NAC is the key factor that influences therapeutic decision-making